Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.83 |
| ▸ | LMNA | P02545 | 5/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.83 |
| ▸ | RAB9A | P51151 | 4/20 | 0.83 |
| ▸ | HTT | P42858 | 4/20 | 0.83 |
| ▸ | HPGD | P15428 | 3/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14614940 | 0.91 | ALDH1A1 (1.00) | NPC1LMNAKDM4ERAB9AHTT | |
| SCHEMBL31465178 | 0.88 | NPC1 (0.71) | NPC1LMNAKDM4ERAB9AHTT | |
| SCHEMBL31465123 | 0.84 | HTT (0.66) | NPC1LMNAKDM4ERAB9AHTT | |
| SCHEMBL12083372 | 0.81 | KDM4E (0.73) | NPC1LMNAKDM4ERAB9AHTT | |
| SCHEMBL30013377 | 0.81 | KDM4E (0.62) | NPC1LMNAKDM4ERAB9AHTT | |
| SCHEMBL13544567 | 0.81 | GAA (0.58) | NPC1LMNAKDM4ERAB9AHTT | |
| SCHEMBL30666379 | 0.80 | ALDH1A1 (0.77) | NPC1LMNAKDM4ERAB9AHTT | |
| SCHEMBL27785753 | 0.80 | NPC1 (0.56) | NPC1LMNAKDM4ERAB9AHTT | |
| SCHEMBL13544831 | 0.79 | NPC1 (0.58) | NPC1LMNAKDM4ERAB9AHTT | |
| SCHEMBL457993 | 0.79 | NPC1 (0.84) | NPC1LMNAKDM4ERAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116616308-A | Application of aromatic formamido-cyclopropane compound in promoting rice growth and development | 郑州郑氏化工产品有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| CN-115515589-A | ULK1/2 inhibitors and methods of use thereof | 萨克生物研究学院 | 2022-12-23 | — | — | CN | disclosed |
| EP-4103182-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Salk Institute for Biological Studies (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-4070795-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3185868-B1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INST FOR BIOLOGICAL STUDI (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2021163629-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-08-19 | — | — | WO | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| CN-1675218-A | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-09-28 | — | — | CN | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| US-20040209879-A1 | Piperidinyl derivates as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20040204408-A1 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | US | disclosed |
| EP-1421082-A1 | NEW PIPERIDINYL-MORPHOLINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| EP-1421070-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003018566-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003018576-A1 | NEW PIPERIDINYL-MORPHOLINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209879-A1 | Piperidinyl derivates as modulators of chemokine receptor activity | CCR2, CXCR1, CCR5 | NPC1 1600/4885LMNA 3886/4885KDM4E 4172/4885 |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | ULK2, ULK1, ULK3 | NPC1 1076/4885LMNA 2963/4885KDM4E 2417/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | NPC1 1196/4885LMNA 1862/4885KDM4E 2324/4885 |
| US-20040204408-A1 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | CCR5, CCR2, CXCR2 | NPC1 875/4885LMNA 3999/4885KDM4E 4616/4885 |
| US-10774092-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | NPC1 860/4885LMNA 4086/4885KDM4E 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.